Related Experiment Video
Updated: Aug 8, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle
Jonathan E Zuckerman1, Ismael Gritli2, Anthony Tolcher3
1Chemical Engineering, California Institute of Technology, Pasadena, CA 91125;
Abstract:
Nanoparticle-based experimental therapeutics are currently being investigated in numerous human clinical trials. CALAA-01 is a targeted, polymer-based nanoparticle containing small interfering RNA (siRNA) and, to our knowledge, was the first RNA interference (RNAi)-based, experimental therapeutic to be administered to cancer patients. Here, we report the results from the initial phase I clinical trial where 24 patients with different cancers were treated with CALAA-01 and compare those results to data obtained from multispecies animal studies to provide a detailed example of translating this class of nanoparticles from animals to humans. The pharmacokinetics of CALAA-01 in mice, rats, monkeys, and humans show fast elimination and reveal that the maximum concentration obtained in the blood after i.v. administration correlates with body weight across all species. The safety profile of CALAA-01 in animals is similarly obtained in humans except that animal kidney toxicities are not observed in humans; this could be due to the use of a predosing hydration protocol used in the clinic. Taken in total, the animal models do appear to predict the behavior of CALAA-01 in humans.
Insights
CALAA-01, a novel nanoparticle therapeutic using small interfering RNA (siRNA), demonstrated predictable pharmacokinetics and safety in human cancer patients, mirroring animal study findings. This translation from animal models to humans offers promise for nanoparticle drug development.
Area of Science:
- Biomedical Engineering
- Translational Medicine
- Nanotechnology in Therapeutics
Background:
- Nanoparticle-based therapeutics are advancing rapidly, with many in clinical trials.
- CALAA-01 represents a pioneering targeted, polymer-based nanoparticle delivering small interfering RNA (siRNA).
- It was the first RNA interference (RNAi)-based therapeutic administered to cancer patients.
Purpose of the Study:
- To report Phase I clinical trial results for CALAA-01 in 24 cancer patients.
- To compare human trial data with multispecies animal study data.
- To exemplify the translation of nanoparticle therapeutics from preclinical animal models to human application.
Main Methods:
- Administered CALAA-01 intravenously to cancer patients.
- Monitored pharmacokinetics and safety profiles in human subjects.
- Compared human data with existing pharmacokinetic and safety data from mice, rats, and monkeys.
Main Results:
- Pharmacokinetics showed rapid elimination across all species, with peak blood concentration correlating to body weight.
- Human safety profiles largely mirrored animal findings.
- Observed absence of kidney toxicity in humans, potentially due to pre-dosing hydration protocols.
Conclusions:
- Animal models effectively predicted the behavior of CALAA-01 in humans.
- The study validates the translational potential of nanoparticle-based siRNA therapeutics.
- CALAA-01's development highlights successful preclinical-to-clinical translation for RNAi therapies.
